Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JONATHAN N YOUSEF

Allopathic & Osteopathic Physicians Family Medicine

NPI
1033170790
CMS profile
274033
Location
WESLEY CHAPEL, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$2,760.71

99 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,560.71 98
Consulting Fee $1,200.00 1

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 2; records 51–99 of 99 matching records. This page contains 49 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JONATHAN N YOUSEF

NPI 1033170790 · CMS profile ID 274033

Allopathic & Osteopathic Physicians / Family Medicine

WESLEY CHAPEL, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–99 of 99 matching records. This page contains 49 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1033170790?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JONATHAN N YOUSEF, NPI 1033170790, CMS profile ID 274033. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–99 of 99 matching records. This page contains 49 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1033170790?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). JONATHAN N YOUSEF, NPI 1033170790, CMS profile ID 274033. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–99 of 99 matching records. This page contains 49 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1033170790?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
JONATHAN N YOUSEF, NPI 1033170790, CMS profile ID 274033, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–99 of 99 matching records. This page contains 49 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1033170790?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

99 matching records · $2,760.71 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 99 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–99 of 99.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Boehringer Ingelheim Pharmaceuticals, Inc. $20.3208/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763706366 CMS
Lilly USA, LLC $13.4408/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818574111 CMS
Horizon Therapeutics plc $17.8908/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797230589 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $15.3808/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850337397 CMS
Amarin Pharma Inc. $21.0307/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815211317 CMS
Amgen Inc. $14.6507/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825454377 CMS
Novo Nordisk Inc $16.0907/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810917199 CMS
Novo Nordisk Inc $5.2607/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811113681 CMS
AbbVie Inc. $27.7207/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796293909 CMS
Kowa Pharmaceuticals America, Inc. $15.5307/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 805603379 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $21.2507/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850364225 CMS
Amarin Pharma Inc. $24.5007/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815381287 CMS
Novo Nordisk Inc $3.5107/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811035357 CMS
Amarin Pharma Inc. $24.4207/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815212975 CMS
Antares Pharma, Inc. $18.6507/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827518115 CMS
Allergan, Inc. $16.6706/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792993235 CMS
Novo Nordisk Inc $6.8506/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811113675 CMS
JAZZ PHARMACEUTICALS INC. $18.7006/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845590673 CMS
Novo Nordisk Inc $4.1406/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810917191 CMS
Novo Nordisk Inc $3.5206/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811152079 CMS
Novo Nordisk Inc $18.4806/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810996065 CMS
Amarin Pharma Inc. $21.3306/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815211311 CMS
Amgen Inc. $14.6205/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826366487 CMS
Kowa Pharmaceuticals America, Inc. $16.5805/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 805603377 CMS
Bioventus LLC $13.2205/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838649241 CMS
Novo Nordisk Inc $5.6405/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811113665 CMS
ARBOR PHARMACEUTICALS, INC. $11.4105/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830951485 CMS
Amarin Pharma Inc. $22.3004/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815211315 CMS
JAZZ PHARMACEUTICALS INC. $11.4704/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845582051 CMS
Takeda Pharmaceuticals U.S.A., Inc. $16.2704/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820348767 CMS
Novo Nordisk Inc $19.0704/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810996059 CMS
Allergan, Inc. $14.4304/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792993233 CMS
Horizon Therapeutics plc $19.9904/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797230587 CMS
AbbVie Inc. $16.4104/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796293907 CMS
Novo Nordisk Inc $21.5804/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811075207 CMS
Amarin Pharma Inc. $9.9204/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815212981 CMS
Novo Nordisk Inc $12.3803/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811113659 CMS
Antares Pharma, Inc. $15.3203/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827473587 CMS
Biohaven Pharmaceuticals, Inc. $6.3003/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852662021 CMS
Novo Nordisk Inc $6.9403/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811075199 CMS
Amgen Inc. $16.5903/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825454369 CMS
Novo Nordisk Inc $10.1803/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811152073 CMS
Novo Nordisk Inc $20.3403/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810996051 CMS
Novo Nordisk Inc $7.0902/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810996045 CMS
Allergan, Inc. $13.6402/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792993231 CMS
Novo Nordisk Inc $22.1302/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811152067 CMS
AbbVie Inc. $14.8802/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796293905 CMS
Novo Nordisk Inc $15.8201/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810996037 CMS
Novo Nordisk Inc $15.8001/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811152107 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,021.85 76
PY2020 $1,543.74 96
PY2021 $2,760.71 99
PY2022 $2,043.99 85
PY2023 $1,404.25 52
PY2024 $1,153.69 46
PY2025 $605.19 29

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,525.99 12
PY2025 Principal investigator $68,591.94 64
PY2024 Principal investigator $83,042.99 6
PY2023 Principal investigator $137,882.02 5
PY2022 Principal investigator $485,133.78 2
PY2021 Principal investigator $1,005,041.10 2
PY2020 Recipient $9,000.00 1
PY2020 Principal investigator $64,248.00 1
PY2019 Principal investigator $12,134.09 5

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

76 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $233.00 12/15/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624602
Principal investigator 1 Boehringer Ingelheim International GmbH $1,915.00 12/15/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624604
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,338.48 12/03/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220994167
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 12/01/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624598
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 12/01/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624600
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $5,007.72 11/25/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220994165
Principal investigator 1 Boehringer Ingelheim International GmbH $3,296.00 11/21/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624590
Principal investigator 1 Boehringer Ingelheim International GmbH $3,296.00 11/21/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624592
Principal investigator 1 Boehringer Ingelheim International GmbH $233.00 11/21/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624594
Principal investigator 1 Boehringer Ingelheim International GmbH $2,627.00 11/21/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624596
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,338.48 11/11/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220994163
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 11/01/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624586
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 11/01/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624588
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 10/27/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220624612
Principal investigator 1 Boehringer Ingelheim International GmbH $2,369.00 10/20/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624582
Principal investigator 1 Boehringer Ingelheim International GmbH $2,490.00 10/20/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624584
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 10/01/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624578
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 10/01/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624580
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 09/01/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624562
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 09/01/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624564
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,338.48 08/22/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220994161
Principal investigator 1 Boehringer Ingelheim International GmbH $1,915.00 08/20/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624570
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 08/01/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624558
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 08/01/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624560
Principal investigator 1 Boehringer Ingelheim International GmbH $79.92 07/28/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624572
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 07/28/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624574
Principal investigator 1 Boehringer Ingelheim International GmbH $3.76 07/28/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624576
Principal investigator 1 Boehringer Ingelheim International GmbH $3,296.00 07/25/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624552
Principal investigator 1 Boehringer Ingelheim International GmbH $2,627.00 07/25/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624554
Principal investigator 1 Boehringer Ingelheim International GmbH $233.00 07/25/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624556
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 07/01/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624566
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 07/01/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624568
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,338.48 06/25/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220994159
Principal investigator 1 Boehringer Ingelheim International GmbH $93.28 06/24/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624548
Principal investigator 1 Boehringer Ingelheim International GmbH $159.84 06/24/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624550
Principal investigator 1 Boehringer Ingelheim International GmbH $34.98 06/24/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220624606
Principal investigator 1 Boehringer Ingelheim International GmbH $359.64 06/24/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220624608
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 06/24/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220624610
Principal investigator 1 Boehringer Ingelheim International GmbH $1,442.00 06/04/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624542
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 06/01/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624538
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 06/01/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624540
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $6,676.96 05/29/2025 Non-covered Recipient Entity
Cozy Research LLC
Ph III HFrEF study No dispute reported 06/30/2026 1220994153
Recipient Boehringer Ingelheim International GmbH $263.22 05/07/2025 Covered Recipient Physician EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220781038
Recipient Boehringer Ingelheim International GmbH $60.06 05/07/2025 Covered Recipient Physician EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220781040
Recipient Boehringer Ingelheim International GmbH $62.39 05/07/2025 Covered Recipient Physician EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220781042
Recipient Boehringer Ingelheim International GmbH $20.00 05/07/2025 Covered Recipient Physician EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220781044
Recipient Boehringer Ingelheim International GmbH $123.97 05/07/2025 Covered Recipient Physician EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220781046
Recipient Boehringer Ingelheim International GmbH $303.60 05/07/2025 Covered Recipient Physician EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220781048
Recipient Boehringer Ingelheim International GmbH $20.00 05/07/2025 Covered Recipient Physician EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220781052
Recipient Boehringer Ingelheim International GmbH $57.19 05/07/2025 Covered Recipient Physician EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220781054
Recipient Boehringer Ingelheim International GmbH $40.45 05/07/2025 Covered Recipient Physician EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220781056
Recipient Boehringer Ingelheim International GmbH $38.36 05/07/2025 Covered Recipient Physician EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220781058
Recipient Boehringer Ingelheim International GmbH $124.99 05/07/2025 Covered Recipient Physician EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220781060
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 05/01/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624534
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 05/01/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624536
Principal investigator 1 Boehringer Ingelheim International GmbH $2,490.00 04/25/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624532
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 04/23/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624544
Principal investigator 1 Boehringer Ingelheim International GmbH $3.10 04/23/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624546
Recipient Boehringer Ingelheim International GmbH $411.76 04/17/2025 Covered Recipient Physician EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220781050
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 04/01/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624528
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 04/01/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624530
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 03/01/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624516
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 03/01/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624518
Principal investigator 1 Boehringer Ingelheim International GmbH $1,915.00 02/25/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624510
Principal investigator 1 Boehringer Ingelheim International GmbH $292.00 02/25/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624522
Principal investigator 1 Boehringer Ingelheim International GmbH $6.96 02/25/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624524
Principal investigator 1 Boehringer Ingelheim International GmbH $3.76 02/25/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624526
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,338.48 02/25/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220994157
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 02/01/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624512
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 02/01/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624514
Principal investigator 1 Boehringer Ingelheim International GmbH $210.00 01/31/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624520
Principal investigator 1 Boehringer Ingelheim International GmbH $3,296.00 01/22/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624502
Principal investigator 1 Boehringer Ingelheim International GmbH $2,627.00 01/22/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624504
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1,669.24 01/08/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220994155
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 01/01/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624506
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 01/01/2025 Non-covered Recipient Entity
Cozy Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624508